fig8

Systemic delivery of large-scale manufactured Wharton's Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction

Figure 8. Myocardial infarction size. (A) Representative Masson’s trichrome staining of heart sections at the midventricular level of each treatment group. (B) Comparative quantification of infarct size percentage. Placebo n = 12, WJMSC-EV-PLT n = 12, WJMSC-EV-FBS n = 7. *P < 0.05. WJMSC: Wharton’s Jelly-derived mesenchymal stem cell; EV: extracellular vesicle; PLT: human platelet lysate; FBS: fetal bovine serum.

The Journal of Cardiovascular Aging

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/